Navigation Links
VolitionRx Files Two Patent Applications
Date:4/4/2013

NAMUR, Belgium, April 4, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics® technology for the detection of histone modifications in nucleosomes; the second covers the use of Volition's Nucleosomics® technology in personalized medicine as a predictor of the efficacy of cancer treatment.

"The use of Nucleosomics in the expanding field of personalized cancer medicine is a new early stage development for us but represents an exciting prospect with the potential for real patient benefit," said Jake Micallef , Chief Scientific Officer of Belgian Volition.

VolitionRx already holds patent applications worldwide for a number of methods of detecting nucleosomes and nucleosome structures; both in-licensed and self-authored.

"These two patents complement our existing Nucleosomics IP, providing us with greater intellectual property protection for our NuQ® products," said Cameron Reynolds , CEO of VolitionRx. "While we work towards applying for regulatory approval for our clinical products in both Europe and the US, we continue to carry out research and development in our Belgian laboratory, expanding our intellectual property base and our understanding of the possibilities – both in diagnostics and therapy monitoring – for our Nucleosomics technology."

About VolitionRx
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRx's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRx at our website at www.volitionrx.com, on Twitter at http://www.twitter.com/VolitionRx, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

Safe Harbor Statement

Statements in this press release may be "forward-looking statements"Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VolitionRx Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
2. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
5. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
6. Sunpeaks Ventures Files Defamation Lawsuit
7. Everett Laboratories, Inc. Files Patent Infringement Lawsuit Against Competitor Trigen Laboratories, Inc.
8. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
9. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
10. Sanford Wittels & Heisler Files $100 Million Gender Discrimination Class Action In Southern District Of New York
11. Acella Pharmaceuticals, LLC, files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration for Topical Corticosteroids Lotion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
Breaking Medicine News(10 mins):